Fresenius commits to more PROSORBA columns:
This article was originally published in Clinica
Executive Summary
Cypress Bioscience has secured further orders from Fresenius Medical Care North America for its PROSORBA column in an expansion to Fresenius' pilot programme of the FDA-approved device. The PROSORBA reduces symptoms in moderate to severe rheumatoid arthritis in hard-to-treat patients. Fresenius has bought a further 1,000 units and will buy a similar number in the third and fourth quarters to support the pilot doctor's office study and hospital use.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.